Unveiling the emergence of SARS-CoV-2 JN.1 sub-variant: Insights from the first cases at Charles Nicolle Hospital, Tunisia
Acta Microbiologica et Immunologica Hungarica · 2024
DOI: 10.1556/030.2024.02247 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Microbiologica et Immunologica Hungarica, 2024. Verfasst von Zaineb Hamzaoui und 15 weiteren Autor:innen. Beteiligte Einrichtung: 1University of Tunis El Manar, Faculty of Medicine of Tunis, LR99ES09, Tunis 1007, Tunisia. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Ministry of Higher Education and Scientific Research of Tunisia.
Abstract (Originalsprache)
The JN.1 sub-variant is a new variant of the SARS-CoV-2 Omicron strain, derived from the BA.2.86 sub-variant. It was first detected in late 2023 and has quickly spread to many countries, becoming the most prevalent variant in some regions. JN.1 exhibits a unique mutation (L455S) in the spike protein compared to the BA.2.86 lineage, which may affect its transmissibility and immune evasion capabilities. JN.1 has been designated as a “variant of interest” by the World Health Organization due to its rapidly increasing spread and is being closely monitored for its impact on the COVID-19 pandemic. This study describes the emergence of SARS-CoV-2 JN.1 sub-variant in Tunisia, and reports its mutation profiles. Nasopharyngeal samples collected over a four-month period (October 2023 to January 2024) were subjected to RNA extraction and real-time RT-PCR confirmation of SARS-CoV-2 infection. The whole-genome sequencing was performed by an iSeq 100 sequencer and COVIDSeq kit reagents (Illumina, USA). Mutation analysis, using the NextClade platform and GISAID database, revealed the presence of JN.1 in 15 out of 80 positive cases (18.75%) during the study period. The emergence of JN.1 highlights the ongoing evolution of SARS-CoV-2 and the need for continued surveillance and research to better understand the characteristics and impact of emerging variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1University of Tunis El Manar, Faculty of Medicine of Tunis, LR99ES09, Tunis 1007, Tunisia.
- 2Charles Nicolle Hospital, Laboratory of Microbiology, Tunis 1006, Tunisia.
- 3National Center Chalbibelkahia of Pharmacovigilance of Tunis, Laboratory of Clinical Pharmacology, 9 Avenue Dr. Zouhaier Essafi 1006 Bab Souika, Tunis, Tunisia.
- 4University of Tunis El Manar, Faculty of Medicine of Tunis, LR16SP02, 1007 Tunis, Tunisia.
ORCID-Profile: Zaineb Hamzaoui
Förderung
- Ministry of Higher Education and Scientific Research of Tunisia
Zitieren
APA
Hamzaoui, Z., Ferjani, S., Kanzari, L., Ben Ali, R., Charaa, L., Landolsi, I., Medini, I., Chammam, S., Abid, S., Ferjani, A., Kebaier, D., Fakhfakh, A., Bouslah, Z., Ben Sassi, M., Trabelsi, S., & Boutiba-Ben Boubaker, I. (2024). Unveiling the emergence of SARS-CoV-2 JN.1 sub-variant: Insights from the first cases at Charles Nicolle Hospital, Tunisia. Acta Microbiologica et Immunologica Hungarica. https://doi.org/10.1556/030.2024.02247
Vancouver
Hamzaoui Z, Ferjani S, Kanzari L, Ben Ali R, Charaa L, Landolsi I, et al. Unveiling the emergence of SARS-CoV-2 JN.1 sub-variant: Insights from the first cases at Charles Nicolle Hospital, Tunisia. Acta Microbiologica et Immunologica Hungarica. 2024. doi:10.1556/030.2024.02247
BibTeX
@article{Hamzaoui2024,
author = {Hamzaoui, Zaineb and Ferjani, Sana and Kanzari, Lamia and Ben Ali, Roua and Charaa, Latifa and Landolsi, Ichrak and Medini, Ines and Chammam, Sarra and Abid, Salma and Ferjani, Asma and Kebaier, Dhouha and Fakhfakh, Ahmed and Bouslah, Zoubeir and Ben Sassi, Mouna and Trabelsi, Sameh and Boutiba-Ben Boubaker, Ilhem},
title = {Unveiling the emergence of SARS-CoV-2 JN.1 sub-variant: Insights from the first cases at Charles Nicolle Hospital, Tunisia},
journal = {Acta Microbiologica et Immunologica Hungarica},
year = {2024},
doi = {10.1556/030.2024.02247}
}
EUVIMED